Wedbush Keeps a Buy Rating on Miragen Therapeutics Inc

Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $19. The company’s shares opened today at $6.95.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 8.9% and a 42.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Miragen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $16.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.91 and a one-year low of $5.01. Currently, Miragen Therapeutics Inc has an average volume of 304.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates, MRG-106 focuses on the treatment of cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth on February 13, 2007 and is headquartered in Boulder, CO.